Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code
31.3.2026 14:00:00 EEST | Business Wire | Press release
Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need.
This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay.
Softr’s new platform was built to bridge the gap between AI-generated prototypes and software that can actually run business operations. Many AI app builders promise instant software from a single prompt, but stop at surface-level outputs, requiring users to manage code, fix errors, and rebuild workflows from scratch. Business software, on the other hand, runs on real data, connects to internal systems, and supports users with defined roles and permissions in real time — it has to work 100 percent of the time. When AI builders fall short or stop at the prototype, only a developer can fix it — resulting in months of work and hundreds of thousands of dollars to get software that should have been ready on day one. Softr closes that gap.
Softr’s new AI-native platform enables organizations to move from fragmented tools to fully operational software systems built in minutes — designed to run securely on live data, integrate with internal infrastructure, and provide structured access and governance from day one.
“For the first time, AI made the idea that ‘I can build something myself’ mainstream for millions of people — but most AI app-builders stop at the shiny demo stage,” said Mariam Hakobyan, Co-Founder and CEO of Softr. “We built Softr to solve the hard parts of software building. Every business app, from an internal HR portal to a client-facing tool, runs on real data, users, permissions, and security. It has to work every single time. Our goal has always been to give non-technical teams the ability to build the custom solutions they need without relying on developers. This evolution turns that vision into reality: software that helps people build and run the mission-critical software that powers their business operations.”
With the addition of Softr’s AI Co-Builder, users can describe the software they need in plain language, and the platform generates a fully integrated system — including the database, user interface, permissions, and business logic — connected and ready for real-world users immediately. Core foundations such as authentication, user roles, permissions, and hosting are built in from the start, eliminating the need for teams to configure or manage them separately.
Softr’s platform is built for business software that teams and customers can depend on every day. Each application is:
- Secure and fully functional from day one, with built-in authentication and permissions
- Powered by a visual, user-friendly database, giving users full control over their data
- Built on custom workflows and integrations, ensuring systems work seamlessly across tools
- Easy to maintain and evolve, without requiring code or repeated prompting
Teams use Softr to power critical workflows such as client portals, CRMs, company intranets, and operational systems across a wide range of industries. The company is now combining that profitable foundation with AI to accelerate its mission: to empower billions of business users to create production-ready software they can rely on from day one.
“The future of software isn’t written — it’s created,” Hakobyan added. “The next generation of software will be built by everyone — not because we simplified code, but because we simplified creation — and made building hard things easy.”
About Softr
Softr is the AI-native platform for building the software your business runs on—portals, internal tools, and operational systems—without code or developers. Describe what you need, and AI creates the database, app, and business logic—already connected, secure, and ready for real users. Over 1M+ organizations, from startups to enterprises like Netflix, Google, Stripe, UPS, and Clay, run their business operations on Softr-built apps. Visit softr.io to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260331754358/en/
Contacts
PR Contact
Kristin Lunt
softr@solcomms.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom